Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15046137 | 0.89 | KIT (0.33) | KITACVRL1 | |
| SCHEMBL15046139 | 0.86 | KIT (0.33) | KITACVRL1 | |
| SCHEMBL15046141 | 0.82 | FGFR1 (0.32) | KIT | |
| SCHEMBL15047911 | 0.76 | FGFR1 (0.35) | ACVRL1 | |
| SCHEMBL15023001 | 0.74 | KIT (0.31) | KIT | |
| SCHEMBL15047962 | 0.73 | ACVRL1 (0.33) | ACVRL1 | |
| SCHEMBL15046128 | 0.72 | KIT (0.46) | KIT | |
| SCHEMBL15047993 | 0.72 | KIT (0.31) | KIT | |
| SCHEMBL4549880 | 0.67 | CSNK1A1 (0.35) | — | |
| SCHEMBL15047900 | 0.67 | FGFR1 (0.38) | ACVRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2791140-B1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | Bayer Pharma AG (DE) | 2016-06-15 | — | — | EP | disclosed |
| US-9206184-B2 | Disubstituted benzothienyl-pyrrolotriazines and uses thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-08 | — | — | US | disclosed |
| WO-2013087578-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-06-20 | — | — | WO | disclosed |
| US-20130158000-A1 | Disubstituted benzothienyl-pyrrolotriazines and uses thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158000-A1 | Disubstituted benzothienyl-pyrrolotriazines and uses thereof | STK25, CDK5, JAK2 | KIT 1382/4885ACVRL1 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.